This activity provides a consolidated overview of biochemical biomarkers reflecting NRF2 pathway activity at the transcriptomic, proteomic, and metabolomic levels. The report integrates evidence from experimental and clinical studies to identify key molecular indicators of NRF2 activation and its downstream effects on oxidative stress, inflammation, and cellular defense mechanisms. These biomarkers include canonical NRF2 target genes (such as NQO1, HO-1, GCLM, and TXNRD1), regulatory proteins involved in redox balance, and metabolic intermediates associated with glutathione metabolism, NADPH production, and lipid peroxidation.
The compilation of these biomarkers supports BenBedPhar’s strategic objective to standardize tools for the quantification of NRF2 activity across laboratories and disease models, thereby improving comparability and reproducibility of data. It also provides a reference framework for the validation of pharmacodynamic responses to NRF2-targeted compounds in preclinical and clinical settings.
Recent scientific evidence, such as our publication “NRF2-dependent molecular signatures in oxidative stress and disease: Biomarkers for translational pharmacology” (Redox Biology, 2024),
https://www.sciencedirect.com/science/article/pii/S2213231724001101?via%3Dihub
underlines the importance of integrating multi-omics biomarkers to monitor NRF2 activation status in vivo. This report builds upon such advances to establish a coherent biochemical reference system that facilitates translational research and supports the discovery of new NRF2 modulators.
Overall, this deliverable reinforces the technological and methodological platform of BenBedPhar, ensuring a unified biochemical basis for evaluating NRF2 activity and guiding pharmacological interventions across multiple noncommunicable diseases.
